lebrikizumab

Ebglyss

Modality

mAb (human IgG4)

Mechanism

Selective IL-13 blockade at high-affinity epitope

Targets

IL-13

Storage

refrigerated 2–8 °C

Approved

atopic dermatitis — FDA 2024

In trial

—

Sources

DailyMed (FDA label)DrugBank ClinicalTrials.gov

Last verified

2026-04-14

No curated MOA diagram yet. See lib/moa-data.ts for the shape; add an entry keyed by lebrikizumab.

Monitoring & workup

Baseline workup

•TB IGRA (or PPD)
•HBV sAg if high risk; HCV Ab if high risk
•Update age-appropriate vaccines before start

Ongoing monitoring

•No routine labs
•Annual TB screening if high exposure risk
•IL-17 class: monitor for candida overgrowth + IBD flare
•IL-23 class: monitor for injection-site reactions